ENSYSCE BIOSCIENCES INC (ENSC) Stock News

USA - NASDAQ:ENSC - US2936025046 - Common Stock

2.11 USD

-0.03 (-1.4%)

Last: 10/28/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ENSC Latest News, Press Relases and Analysis

All

Press Releases

16 days ago - By: Benzinga - Mentions: NDRA POAI ADTX NBTX ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

19 days ago - By: ACCESS Newswire

Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025

2 months ago - By: ACCESS Newswire

Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

2 months ago - By: ACCESS Newswire

Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

3 months ago - By: The Motley Fool

Ensysce Biosciences Narrows Loss in Q2

3 months ago - By: ACCESS Newswire

Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

3 months ago - By: Benzinga - Mentions: PBM ALGN DYAI SNGX ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

3 months ago - By: ACCESS Newswire

Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

3 months ago - By: ACCESS Newswire

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

4 months ago - By: ACCESS Newswire

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

5 months ago - By: ACCESS Newswire

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

5 months ago - By: ACCESS Newswire

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

6 months ago - By: ACCESS Newswire

Ensysce Biosciences Reports First Quarter 2025 Financial Results

6 months ago - By: ACCESS Newswire

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

6 months ago - By: ACCESS Newswire

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

7 months ago - By: ACCESS Newswire

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

7 months ago - By: ACCESS Newswire

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

6 months ago - By: ACCESS Newswire

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

8 months ago - By: ACCESS Newswire

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

6 months ago - By: ACCESS Newswire

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

7 months ago - By: Stocktwits - Mentions: VXF GM

Ensysce Biosciences Stock Rises On Positive Data From Opioid Overdose Protection Study: Retail’s Thrilled

7 months ago - By: ACCESS Newswire

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

8 months ago - By: ACCESS Newswire

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

8 months ago - By: Today's Marketplace

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids